4-(4-bromo-3,5-dimethylpyrazol-1-yl)-6-[[4-ethyl-3-(4-fluorophenyl)-1-methylpyrazol-5-yl]methyl]pyrimidine
C22H22BrFN6 — CID 159575169
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-(4-bromo-3,5-dimethylpyrazol-1-yl)-6-[[4-ethyl-3-(4-fluorophenyl)-1-methylpyrazol-5-yl]methyl]pyrimidine
4-(4-bromo-3,5-dimethylpyrazol-1-yl)-6-[[4-ethyl-3-(4-fluorophenyl)-1-methylpyrazol-5-yl]methyl]pyrimidine (PubChem CID 159575169) has the molecular formula C22H22BrFN6 and a molecular weight of 469.36 g/mol. Its IUPAC name is 4-(4-bromo-3,5-dimethylpyrazol-1-yl)-6-[[4-ethyl-3-(4-fluorophenyl)-1-methylpyrazol-5-yl]methyl]pyrimidine.
Molecular Properties
| Compound Name | 4-(4-bromo-3,5-dimethylpyrazol-1-yl)-6-[[4-ethyl-3-(4-fluorophenyl)-1-methylpyrazol-5-yl]methyl]pyrimidine |
|---|---|
| PubChem CID | 159575169 |
| Molecular Formula | C22H22BrFN6 |
| Molecular Weight | 469.36 g/mol |
| Exact Mass | 468.11 |
| IUPAC Name | 4-(4-bromo-3,5-dimethylpyrazol-1-yl)-6-[[4-ethyl-3-(4-fluorophenyl)-1-methylpyrazol-5-yl]methyl]pyrimidine |
| SMILES | CCc1c(-c2ccc(F)cc2)nn(C)c1Cc1cc(-n2nc(C)c(Br)c2C)ncn1 |
| InChI | InChI=1S/C22H22BrFN6/c1-5-18-19(29(4)28-22(18)15-6-8-16(24)9-7-15)10-17-11-20(26-12-25-17)30-14(3)21(23)13(2)27-30/h6-9,11-12H,5,10H2,1-4H3 |
| InChIKey | MIHSZLAFQUKZCI-UHFFFAOYSA-N |
| XLogP | 4.73 |
| TPSA | 61.42 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 469.36 |
| LogP ≤ 5 | 4.73 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 159575169 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.